Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

218697 Casein Kinase II Inhibitor I - CAS 17374-26-4 - Calbiochem

218697
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

Empirical FormulaCAS #
C₆HBr₄N₃ 17374-26-4

Products

Número de referenciaEmbalaje Cant./Env.
218697-10MG Ampolla de plást. 10 mg
Description
OverviewA cell-permeable benzotriazolo compound that acts as a higly selective, reversible, and ATP/GTP-competitive inhibitor of casein kinase-2 (CK2) (IC50 = 900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively) and DYRK (IC50 < 1 µM for DYRK1a). Its specificity has been demonstrated using a panel of 33 kinases, including PKA, PKB, PKC, MKK1, Erk2, p38, JNK, Lck, Lyn, and Syk. Also shown to inhibit NS3-associated viral helicase activities in HCV (IC50 = 20 and 60 µM, using DNA and RNA substrate, respectively) and WNV (IC50 = 1.7 and 900 nM, using DNA and RNA substrate, respectively). A 10 mM (5 mg/1.15 ml) solution of Casein Kinase II Inhibitor I (Cat. No. 218708) in DMSO, is also available.
Catalogue Number218697
Brand Family Calbiochem®
SynonymsTBB, TBBt, 4,5,6,7-Tetrabromobenzotriazole, 4,5,6,7-Tetrabromo-2-azabenzimidazole, CK2 Inhibitor
References
ReferencesBorowski, P., et al. 2003. Eur. J. Biochem. 270, 1645.
Sarno, S., et al. 2003. Biochem. J. 374, 639.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun. 306, 129.
Ruzzene, M., et al. 2002. Biochem. J. 364, 41.
Sarno, S., et al. 2001. FEBS Lett. 496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun. 208, 418.
Product Information
CAS number17374-26-4
ATP CompetitiveY
FormWhite solid
Hill FormulaC₆HBr₄N₃
Chemical formulaC₆HBr₄N₃
ReversibleY
Structure formula ImageStructure formula Image
Applications
ApplicationCasein Kinase II Inhibitor I, CAS 17374-26-4, is a cell-permeable, selective, reversible, and ATP/GTP-competitive inhibitor of casein kinase-2 (IC50 = 900 nM for rat liver CK2).
Biological Information
Primary TargetCK2 rat liver, human recombinant
Primary Target IC<sub>50</sub>900 nM and 1.6 µM, using rat liver and human recombinant CK2, respectively; < 1 µM for DYRK1a
Purity≥99% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Carcinogenic / Teratogenic
Storage +2°C to +8°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications

Documentation

Casein Kinase II Inhibitor I - CAS 17374-26-4 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Casein Kinase II Inhibitor I - CAS 17374-26-4 - Calbiochem Certificados de análisis

CargoNúmero de lote
218697

Referencias bibliográficas

Visión general referencias
Borowski, P., et al. 2003. Eur. J. Biochem. 270, 1645.
Sarno, S., et al. 2003. Biochem. J. 374, 639.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun. 306, 129.
Ruzzene, M., et al. 2002. Biochem. J. 364, 41.
Sarno, S., et al. 2001. FEBS Lett. 496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun. 208, 418.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision07-January-2009 JSW
SynonymsTBB, TBBt, 4,5,6,7-Tetrabromobenzotriazole, 4,5,6,7-Tetrabromo-2-azabenzimidazole, CK2 Inhibitor
DescriptionA cell-permeable benzotriazolo compound that acts as a highly selective, ATP/GTP-competitive casein kinase II (CKII) inhibitor (IC50 = 900 nM and 1.6 µM for rat liver and human recombinant CKII, respectively) and DYRK (IC50 <1 µM for DYRK1a). Specificity for CKII has been reported following the screening of 33 kinases, including PKA, Akt, PKC, MKK1, ERK2, p38, JNK, Lck, Lyn, and Syk. Also reported to inhibit NS3-associated viral helicase activity in hepatitis C virus (HCV) (IC50 = 20 and 60 µM using DNA and RNA substrates, respectively) and West Nile virus (WNV) (IC50 = 1.7 µM and 900 nM using DNA and RNA substrates, respectively).
FormWhite solid
Intert gas (Yes/No) Packaged under inert gas
CAS number17374-26-4
Chemical formulaC₆HBr₄N₃
Structure formulaStructure formula
Purity≥99% by HPLC
SolubilityDMSO (10 mg/ml)
Storage +2°C to +8°C
Protect from light
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity Carcinogenic / Teratogenic
ReferencesBorowski, P., et al. 2003. Eur. J. Biochem. 270, 1645.
Sarno, S., et al. 2003. Biochem. J. 374, 639.
Zien, P., et al. 2003. Biochem. Biophys. Res. Commun. 306, 129.
Ruzzene, M., et al. 2002. Biochem. J. 364, 41.
Sarno, S., et al. 2001. FEBS Lett. 496, 44.
Szyszka, R., et al. 1995. Biochem. Biophys. Res. Commun. 208, 418.